There is a continuous debate about the risks of increased incidence of COVID-19 in
vulnerable patient groups, which includes patients with rheumatic diseases and especially …

Comment e676 www. thelancet. com/rheumatology Vol 3 October 2021 8375 [90· 1%]
women and 893 [9· 6%] men) between April 3 and May 8, 2020. The most frequent …

Although viruses can induce rheumatic diseases, the impact of SARS-CoV-2, the virus
behind COVID-19, on the development of systemic rheumatic disease is unclear. COVID-19 …

Early in the COVID-19 pandemic, there was concern in the media that the use of non-
steroidal antiinflammatory drugs (NSAIDs), particularly ibuprofen, might exacerbate COVID …

We read with interest the studies by Renaud Felten and colleagues1 and Laura Boekel and
colleagues2 published in The Lancet Rheumatology, which both contribute essential …

With the COVID-19 pandemic, there has been great uncertainty about whether the virus
could exacerbate autoimmune diseases such as rheumatoid arthritis given that infection can …

Vaccination is an important and effective tool to prevent infections in the general population,
as well as in patients with autoimmune and inflammatory rheumatic diseases. It has been …

March 23. DOI: 10.1093/ofid/ofaa105. 5 Wu C, Chen X, Cai Y, et al. Risk factors associated
with acute respiratory distress syndrome and death in patients with coronavirus disease …

In December, 2019, an outbreak of the novel coronavirus (SARS-CoV-2) that causes
coronavirus dis ease 2019 (COVID-19) occurred in Wuhan, China, 1 and soon spread all …

This is the largest prospective study to investigate clinical outcomes related to breakthrough
infection and was adequately sized to investigate specific immunosuppressive medications …